Testosterone Treatments Come Under Fire in Some 220 Cases Now Filed in Illinois Federal Court Litigation

Share Article

The Firm is evaluating testosterone lawsuits on behalf of men who allegedly suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism and other serious cardiovascular problems as a result of certain hormone replacement therapies.

Free Case Review
Our Firm has heard from numerous men who allege serious cardiovascular problems caused by low-testosterone treatments.

More than 220 testosterone lawsuits (http://www.consumerinjurylawyers.com/dangerous-drugs/testosterone-lawsuit/) have now been filed in the U.S. District Court, Northern District of Illinois, where cases involving a number of prescription hormone therapies have been centralized in a federal multidistrict litigation, Bernstein Liebhard LLP reports.

A Case List updated on October 15th shows 223 claims now pending in the Northern District of Illinois on behalf of individuals who allegedly suffered strokes, heart attacks, deep vein thrombosis, pulmonary embolism and other serious cardiovascular problems as a result of AndroGel, Testim, Axiron and other prescription therapies. According to claims, the makers of these products failed to adequately warn about their alleged side effects, which may be life-threatening. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)

“Our Firm has heard from numerous men who allege serious cardiovascular problems caused by low-testosterone treatments. Our attorneys are following developments in the federal litigation closely,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently evaluating legal claims on behalf of men who experienced serious heart problems allegedly due to the use of AndroGel, Axiron and other testosterone medications.

Testosterone Lawsuits
According to court records, testosterone lawsuits now filed in the Northern District of Illinois similarly accuse the drug manufacturers of concealing vital safety information about their products from the public. Plaintiffs further allege that the makers of AndroGel and other medications marketed them for age-related “Low T,” a condition that manifests in low libido, sexual dysfunction, fatigue and other common symptoms of aging. These uses are considered off-label, as prescription testosterone therapies are right now only approved by the U.S. Food and Drug Administration (FDA) to treat men with hypogonadism, or abnormally-low levels of the hormone, caused by an underlying medical condition. By promoting testosterone treatments for uses not approved by the FDA, thousands of men may have been unknowingly placed at risk for serious cardiovascular injuries, plaintiffs further allege.

The litigation involving AndroGel and other widely-used hormone therapies has been increasing steadily since January 2014, when the FDA noted the findings of research that showed an increased heart attack risk in men older than 65 and younger men with a pre-existing history of heart disease. That September, a panel of FDA advisors voted 20-1 to adjust labeling on testosterone products so that they clearly state the lack of evidence proving their safety and efficacy in treating low libido and other aging symptoms. Manufacturers of AndroGel and other medications should also be required to conduct safety studies of their alleged cardiovascular side effects.*

Men who suffered heart attacks, strokes, or other cardiovascular problems allegedly related to a testosterone treatment may be entitled to compensation for medical bills, lost wages, pain and suffering and more. Find out more recent news involving testosterone treatments when you visit Bernstein Liebhard LLP’s website, or call 800-511-5092 for a free case review.

*reuters.com/article/2014/09/17/us-usa-health-testosterone-idUSKBN0HC2C320140917, Reuters, September 18, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website